Class Action Cases

Perjeta and Herceptin is only marginally more effective than Herceptin alone in preventing breast cancer. Click "Join this Class Action" above.

Attorneys

Roche Holding AG

Join Class Action »

The Pawar Law Group announces a class action lawsuit on behalf of Roche Holding AG (RHHBY) investors who purchased Roche Holding AG stock between March 2, 2017 and June 5, 2017, inclusive (the “Class Period”). The suit is for recovery of investor losses.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

Press Release

According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) the combination of Perjeta and Herceptin is only marginally more effective than Herceptin alone in preventing breast cancer; and (2) as a result, Defendants’ statements about Roche’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.

If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You may join the case here: http://pawarlawgroup.com/cases/roche/ or email Vik Pawar, Esq. at vik@pawarlawgroup.com

——————————-

Contact:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (212) 571-0805
Fax: (212) 571-0938
vik@pawarlawgroup.com